¹⁷⁷Lu-DPI-4452 is a ¹⁷⁷Lu labeled peptide developed for the treatment of of carbonic anhydrase IX (CAIX) expressing solid tumors. It is developed as a radiotheranostic pair with the ⁶⁸Ga-analogue ⁶⁸Ga-DPI-4452 in patients with locally advanced renal, pancreatic, and colorectal cancer. A phase I/II involving 147 patients has been initiated in March 2023 in Australia.

Target/Mechanism: CAIX

Carrier/Ligand: DPI-4452

Radiation Type: beta electrons (β^–)